健康元：公司流感创新药壹立康的医院准入工作正按计划有序推进

Core Viewpoint - The company is actively participating in global pharmaceutical industry events and is closely monitoring cutting-edge technology developments and industry trends, including brain-computer interfaces [2] Group 1: Company Initiatives - The company is advancing its innovative flu drug, Yilikan, with hospital access work proceeding as planned [2] - The company is actively collaborating with local channels and medical institutions to expedite the drug's entry into hospitals, ensuring rapid access for patients [2] Group 2: Strategic Focus - The company is conducting careful research and planning for technological developments in line with its strategic growth needs, with commitments to timely information disclosure on any substantial progress [2]